RIDASCREEN® IFX Monitoring is an enzyme linked immunoassay intended for the quantitative determination of infliximab (IFX, anti-TNFα) in human serum and plasma.
It is the commercialized CE-registered version of KU Leuvens home-brew assay, who is leading the way in therapeutic drug monitoring (TDM). It was used in the TAXIT study*, which showed the positive effect of TDM for therapy- and cost-optimization.
Infliximab is a chimeric antibody directed against the pro-inflammatory cytokine TNFα, a so-called TNFα-blocker. It is used for a number of inflammatory diseases such as Ulcerative colitis and Crohn’s disease.
Due to individual pharmacokinetics, different people show different drug levels in the blood even though they receive identical IFX dosage. However, a certain drug concentration in the patient’s blood must be present in order to be effective.
Testing of IFX concentration
By therapeutic drug monitoring this can be checked and the dosage can be optimally adjusted to the individual needs of the patient. For this purpose, the IFX drug concentrations in the blood are tested before the next infusion (trough level concentration).
* Vande Casteele N. et al, OP001 Randomised controlled trial of drug level versus clinically based dosing of Infliximab maintenance therapy in IBD: Final results of the TAXIT study. UEG Journal 2013.
Interested in therapeutic drug monitoring of Infliximab? Contact us, view the product details of RIDASCREEN® IFX Monitoring, or learn more about our partnership opportunities for personalized solutions.